. . World News – CA – Novavax Slides After U. . S.. . Covid-19 vaccine trial delayed again


. .

Novavax Inc. . Stocks fell 6. 5% before the bell on Monday after the start of a large-scale U. . S.. . and the vaccine trial against Mexico Covid-19 has been postponed for the second time.

The Phase 3 trial was originally scheduled to begin in mid-October, before the Gaithersburg, Maryland-based company rescheduled the start date to late November. Novavax now expects the study to begin in the coming weeks, the company said in a statement. Novavax is working closely with the Food and Drug Administration to maintain a Fujifilm Diosynth Biotechnologies site for commercial scale production.

Vaccine Guide Pfizer Inc. . and BioNTech SE have already requested emergency approval for their recordings, while Moderna Inc. . said it plans to file today. The Food and Drug Administration is expected to meet in December. 10 to discuss Pfizer vaccination and will likely discuss Moderna’s December shot. 17, according to the company. The two leading recordings use messenger RNA technology, while Novavax’s vaccine is made of synthetic spike proteins grown in moth cells.

Novavax is up more than 3 this year. 000% increased. The program is supported by $ 1. 6 billion funding from Operation Warp Speed, the U. . S.. . Government plan to accelerate the development of vaccinations for the novel coronavirus.

Novavax, Inc, Vaccine, NASDAQ: NVAX, Moderna, Clinical Trial

World News – CA – Novavax Slides After U. . S.. . Covid-19 vaccine trial delayed again
. . Related Title :
>> Novavax Slides after US Covid-19 vaccine study delayed again
>> Novavax sees the US COVID-19 vaccine trial begin in the coming weeks after the second delay
What Coronavirus Vaccine Should You Get? A Subjective Guide.
> Novavax shares slide on US coronavirus vaccine trials in after second delay Late-stage from
Why Novavax Could Be a Bigger COVID Vaccine Winner Than Pfizer and Moderna
Novavax announces advances in clinical development of COVID-19 vaccines
For Novavax Inc. . [NVAX] analyst sees an increase to $ 290. What’s next?
Novavax (NASDAQ: NVAX) announces delay in coronavirus test
>> Rival COVID-19 vaccine makers report AstraZeneca hiccups s = Novavax slips after updating COVID-19 vaccine by 6% « > Novavax slipping by 6% after updating COVID-19 vaccine

Ref: https://www.bloomberg.com


Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]